Advances on the roles of tenascin-C in cancer
Yilmaz, Alev; Loustau, Thomas; Salomé, Nathalie; Poilil Surendran, Suchithra; Li, Chengbei; Tucker, Richard P.; Izzi, Valerio; Lamba, Rijuta; Koch, Manuel; Orend, Gertraud (2022-09-14)
Alev Yilmaz, Thomas Loustau, Nathalie Salomé, Suchithra Poilil Surendran, Chengbei Li, Richard P. Tucker, Valerio Izzi, Rijuta Lamba, Manuel Koch, Gertraud Orend; Advances on the roles of tenascin-C in cancer. J Cell Sci 15 September 2022; 135 (18): jcs260244. doi: https://doi.org/10.1242/jcs.260244
© 2022. Published by The Company of Biologists Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
https://creativecommons.org/licenses/by/4.0/
https://urn.fi/URN:NBN:fi-fe2022101461991
Tiivistelmä
Abstract
The roles of the extracellular matrix molecule tenascin-C (TNC) in health and disease have been extensively reviewed since its discovery over 40 years ago. Here, we will describe recent insights into the roles of TNC in tumorigenesis, angiogenesis, immunity and metastasis. In addition to high levels of expression in tumors, and during chronic inflammation, and bacterial and viral infection, TNC is also expressed in lymphoid organs. This supports potential roles for TNC in immunity control. Advances using murine models with engineered TNC levels were instrumental in the discovery of important functions of TNC as a danger-associated molecular pattern (DAMP) molecule in tissue repair and revealed multiple TNC actions in tumor progression. TNC acts through distinct mechanisms on many different cell types with immune cells coming into focus as important targets of TNC in cancer. We will describe how this knowledge could be exploited for cancer disease management, in particular for immune (checkpoint) therapies.
Kokoelmat
- Avoin saatavuus [31650]